���存条件与分析表征方法 — Reference Sheet

By Editorial Desk · published 2026-04-22 · last reviewed 2026-06-11 · Topic

reconstitution is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2026-06-11. Numbers and descriptions here follow the published literature rather than marketing material.

储存条件与分析表征方法

关于降解产物的免疫原性风险，文献中仍有讨论空间。体外聚集水平与临床免疫反应之间的定量关系尚未确立。多数公开研究只报告理化指标，缺少长期随访的对应数据。这一问题在生物类似物比对中尤其受到关注。

市售注射用制剂通常要求在二至八摄氏度冷藏保存，并避免光照与冻结。部分多剂量笔在首次使用后允许在不超过三十摄氏度的环境中存放有限周数，具体期限由辅料与防腐剂体系决定。反复冻融会促进肽链聚集并改变可见颗粒计数，因此应予避免。冻干粉末在干燥、避光、低温条件下更为稳定。溶液配制后宜使用低吸附容器，以减少肽类在塑料或玻璃表面的损失。

Storage, Handling, and Analytical Verification

Material described as research-grade is not necessarily manufactured to pharmaceutical standards, and purity figures depend on the method used to obtain them. A certificate of analysis states the measured purity, the analytical technique, and the batch identifier, but the underlying data are not always included. Independent testing by a second laboratory is a common way to confirm identity and purity. Uncertainties remain about how storage history affects long-term stability, and about how well results from one laboratory transfer to another. Documentation of handling conditions supports comparison between batches.

Peptides are sensitive to temperature, light, oxygen, and repeated freeze-thaw cycles. Semaglutide in dry form is generally held at refrigerated temperatures, while reconstituted solutions require a defined short-term storage window. Vials should be kept in secondary packaging to limit photodegradation, and exposure to alkaline conditions is avoided because it accelerates chemical degradation. Adsorption to glass and some plastics can reduce the measured concentration of dilute solutions, so low-binding polypropylene containers are preferred for analytical work. Each transfer step introduces a small risk of contamination, and closed handling practices reduce that risk.

Semaglutide at a glance

Handling, Storage, and Analysis

Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.

Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.

Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.

Related pages on this site

• Portable summary
• Focused trends
• Focused checklist
• Measured update
• Efficient checklist
• Sustainable primer
• Material primer
• Simple guide

Handling, Storage, and Quality Control

Handling practices center on minimizing contamination and adsorption. Lyophilized peptide tends to accumulate static charge, so weighing is done with antistatic measures and calibrated balances. Reconstitution with appropriate solvent should be gentle, avoiding vigorous vortexing that generates foam and shear. Solutions are typically aliquoted before freezing to reduce repeated temperature cycling. Personal protective equipment and a fume hood are standard for powder handling.

Reconstituted solutions are less stable than the dry powder, and stability depends on concentration, pH, buffer composition, and container material. Low-protein-binding tubes reduce loss of peptide to plastic surfaces. Some researchers add a carrier protein to limit adsorption at low concentrations. The exact shelf life of a given solution is best determined empirically through a stability study rather than assumed from general guidance, because published data cover only a limited set of conditions.

Storage, Stability, and Analytical Control

Lyophilised semaglutide is generally held at -20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept at 2-8 °C and used within a defined window because degradation accumulates over time. Repeated freeze-thaw cycles are discouraged, since each cycle can promote aggregation and reduce monomeric content. Room-temperature stability of the solid has been examined in some studies but remains incompletely characterised for long durations, so cold storage is the conservative default for research material.

Degradation proceeds along several parallel routes. Deamidation of asparagine and glutamine residues generates charged variants that shift retention time in chromatographic analysis. Oxidation targets methionine and can be accelerated by trace metals or dissolved oxygen. Non-covalent aggregation produces dimers, oligomers, and larger species that are difficult to reverse. Isomerisation at aspartate residues is slower but measurable under thermal stress. The distribution among these pathways depends on pH, buffer composition, ionic strength, and the presence of excipients such as sugars or surfactants.

Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 nm is the standard purity method, reported as area percent. Mass spectrometry, usually with electrospray ionisation, confirms identity and reveals covalent modifications. Size-exclusion chromatography quantifies aggregates and fragments. Peptide mapping after enzymatic digestion localises changes to specific sequence regions. Circular dichroism and infrared spectroscopy report on secondary structure, while light scattering tracks particle formation in liquid formulations. No single technique captures every quality attribute.

Molecular Background and Drug Class

Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.

Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.

Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.

Reference notes

== Structure == Mammalian GPX1, GPX2, GPX3, and GPX4 (this protein) have been shown to be selenium-containing enzymes, whereas GPX6 is a selenoprotein in humans with cysteine-containing homologues in rodents. In selenoproteins, the amino acid selenocysteine is inserted in the nascent polypeptide chain during the process of translational recoding of the UGA stop codon. GPX4 shares the amino acid motif of selenocysteine, glutamine, and tryptophan (catalytic triad) with other glutathione peroxidases.

The following is a partial list of the "E" codes for Medical Subject Headings (MeSH), as defined by the United States National Library of Medicine (NLM). This list continues the information at the List of MeSH codes (E04). Codes following these are found in the List of MeSH codes (E06). For other MeSH codes, see List of MeSH codes. The source for this content is the set of 2006 MeSH Trees from the NLM.

The biochemical mechanism of VOC generation in the human body is not fully comprehended. Their occurrence is due to changes in cell metabolism, inflammation, and oxidative stress, where reactive oxygen species (ROS) produced from cellular respiration interact with cellular structures (such as the membrane, proteins, DNA, and RNA) to create VOCs. The accumulation occurs in breath, skin, sweat, blood, urine, and faeces. The samples can be analyzed by various methods, such as selected-ion-flow-tube mass spectrometry (SIFT-MS), field asymmetric ion mobility spectrometry (FAIMS), nuclear magnetic resonance (NMR) spectroscopy, proton-transfer-reaction mass spectrometry (PTR-MS) and more, but the commonly used technologies are gas chromatography with mass spectrometry (GC-MS) and electric nose (e-nose). The difference in samples and methods of analysis chosen may explain the high heterogeneity observed in VOCs identified in different studies pertaining to the same diseases.

== History == It is generally accepted that dry ice was first observed in 1835 by French inventor Adrien-Jean-Pierre Thilorier (1790–1844), who published the first account of the substance. In his experiments, he noted that when opening the lid of a large cylinder containing liquid carbon dioxide, most of the liquid carbon dioxide quickly evaporated. This left only solid dry ice in the container. In 1924, Thomas B. Slate applied for a US patent to sell dry ice commercially. Subsequently, he became the first to make dry ice successful as an industry. In 1925, this solid form of CO2 was trademarked by the DryIce Corporation of America as "Dry ice", leading to its common name. That same year the DryIce Co. sold the substance commercially for the first time, marketing it for refrigeration purposes.

=== Color === Whiteness of tofu is determined by soybean variety, soybean protein composition, and degree of aggregation of the tofu gel network. The yellowish-beige color of soybeans is due to the color compounds including anthocyanin, isoflavones, and polyphenol compounds; therefore the soybean variety used will predicate the color of the final tofu product. Ways to reduce the yellow color include reducing isoflavone content by changing the pH of the soy milk solution used in the production of the tofu so that the relevant compounds precipitate out and are removed during the extraction of okara. The opacity of tofu gel and the off-white color typical of standard uncooked firm tofu is due to the scattering of light by the colloidal particles of the tofu. The addition of higher levels of calcium salts or a high protein content will contribute to forming a denser and more aggregated gel network which disperses more light, resulting in tofu with a whiter appearance.

Sources: en.wikipedia.org

Reference notes

===== MeSH D08.811.682.732 – peroxidases ===== MeSH D08.811.682.732.332 – catalase MeSH D08.811.682.732.360 – chloride peroxidase MeSH D08.811.682.732.380 – cytochrome-c peroxidase MeSH D08.811.682.732.440 – eosinophil peroxidase MeSH D08.811.682.732.500 – glutathione peroxidase MeSH D08.811.682.732.512 – horseradish peroxidase MeSH D08.811.682.732.512.900 – wheat germ agglutinin-horseradish peroxidase conjugate MeSH D08.811.682.732.525 – iodide peroxidase MeSH D08.811.682.732.550 – lactoperoxidase MeSH D08.811.682.732.700 – peroxidase

=== Multidisciplinary doctoral programme === Has been instituted for students who have completed masters in any relevant discipline of natural sciences, medicine, engineering and other related sciences. RCB recruits Junior Research Fellowships (JRFs) twice during an academic year and already mentors 31 Research Fellows.

In a study on dinosterol side chain synthesis in the marine heterotrophic dinoflagellate, Crypthecodinium cohnii, the dinoflagellates were cultured with methionine-[CD3]. GC-MS analysis revealed that the C-23 methyl group contained three deuterium atoms that were introduced by transmethylation from methionine. The C-24 methyl group contained only two deuterium atoms, consistent with a 24-methylenesterol intermediate, which is reduced to the resulting 24-methyl side chain. This mechanism has been previously reported in fungi, a chrysophyte alga and a diatom. Importantly, no deuterium was incorporated into cholesterol or cholesta-5,7-dien-3β-ol, which are the major 4-methyl-sterols in Crypthecodinium cohnii. A suggested biosynthetic mechanism for side chain alkylations at C-23 and C-24 in dinosterol has been proposed.

== Applications == In biochemistry, the process of breaking down large molecules by splitting their internal bonds is catabolism. Enzymes which catalyse bond cleavage are known as lyases, unless they operate by hydrolysis or oxidoreduction, in which case they are known as hydrolases and oxidoreductases respectively. In proteomics, cleaving agents are used in proteome analysis, where proteins are cleaved into smaller peptide fragments. Examples of cleaving agents used are cyanogen bromide, pepsin, and trypsin.

Sources: en.wikipedia.org

Frequently asked questions